Eli Lilly (LLY) reported Q4 EPS of $7.54 versus $6.67 expected. Eli Lilly projected 2026 revenue of $80-83B. Eli Lilly’s Mounjaro revenue surged 110% to $7.4B in Q4. Zepbound revenue jumped 123% to $4 ...

But there's a powerful fundamental story happening with Eli Lilly. Also, EPS is estimated to ramp higher this year by +21.7%.

Eli Lilly topped Novo in terms of both revenue and net income. Moderna’s stable financials were overshadowed by the regulatory whiplash it experienced in mid-February. Similarly, the vaccine segments ...

Eli Lilly is upgraded to Buy after a 13% pullback and strong Q4 guidance, with potential for 25% topline growth in 2026. LLY's acquisition of Kelonia and Orna Therapeutics positions it at the ...

Monday, July 6, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co ...

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark Large Growth Fund” Q4 2025 investor letter. A copy of the letter can be ...

Eli Lilly and Company LLY announced robust fourth-quarter results on Feb. 4. Lilly beat estimates for both earnings and sales and issued an upbeat guidance for 2026. Adjusted earnings per share of ...

Mon, February 16, 2026 at 7:00 PM UTC As of February 13, 2026, shares of Eli Lilly (NYSE:LLY) were trading at $1,040, just 5.8% below the stock's all-time high. Retail sentiment has turned decisively ...